Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer

Acta Oncologica

Volumn 49, Issue 6, 2010, Pages 797-804

  Öhrling, Katarina ^a   Edler, David ^b   Hallström, Marja ^a   Ragnhammar, Peter ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; FLUOROURACIL; FORMALDEHYDE; MISMATCH REPAIR PROTEIN; MLH1 ANTIBODY; MSH2 ANTIBODY; PARAFFIN; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DNA MISMATCH REPAIR; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; NEOPLASM STAGING; NUCLEAR PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77954478010     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/02841861003705786     Document Type: Article

References (36)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
2. Allen WL, Johnston PG. Role of genomic markers in colorectal cancer treatment. J Clin Oncol 2005;23:4545-4552
3. Fearon ER, Vogelstein B. A genetic model for colorectal tumorgenesis. Cell 1990;61:759-767
4. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997;57:808-811
5. Jass JR. Classifi cation of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007;50:103-130
6. Cawkwell L, Gray S, Murgatroyd H, Sutherland F, Haine L, Longfellow M, et al. Choice of management strategy for colorectal cancer based on a diagnostic immunohistochemical test for defective mismatch repair. Gut 1999;45:409-415
7. Marcus VA, Madlensky L, Gryfe R, Kim H, So K, Millar A, et al. Immunohistochemistry for hMLH1 and hMSH2: A practical test for DNA mismatch repair-defi cient tumours. Am J Surg Pathol 1999;23:1248-1255
8. Lanza G, Gafà R, Maestri I, Santini A, Matteuzzi M, Cavazzini L. Immunohistochemical pattern of MLH1/MSH2 expression is related to clinical and pathological features in colorectal adenocarcinomas with microsatellite instability. Mod Pathol 2002;5:741-749
9. Stone JG, Robertson D, Houlston RS. Immunohistochemistry for MSH2 and MLH1: A method for identifying mismatch repair defi cient colorectal cancer. J Clin Pathol 2001; 54:484-487
10. Lindor NM, Burgart LJ, Leontovich O, Goldberg RM, Cunningham JM, Sargent DJ, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 2002;20:1043-1048
11. Elsaleh H, Powell B, McCaul K, Grieu F, Grant R, Joseph, et al. p53 alterations and microsatellite instability have predictive value for survival benefi t from chemotherapy in stage III colorectal cancer. Clin Cancer Res 2001;7:1343-1349
12. Gryfe R, Kim H, Hsieh ETK, Aronson MD, Holowaty EJ, Bull SB, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000;342:69-77.
13. Lanza G, Gafa R, Santini A, Maestri I, Guerzoni L, Cavazzini L. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J Clin Oncol 2006;24:2359-2367
14. M alesci A, Laghi L, Bianchi P, Delconte G, Randolph A, Torri V, et al. Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. Clin Cancer Res 2007;13:3831-3839
15. Tejpar S, Bosman F, Delorenzi M, Fiocca R, Yan P, Klingbiel D, et al. Microsatellite (MSI) in stage II and stage III colon cancer treated with 5-FU-LV or 5-FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial). J Clin Oncol 2009;27:15S (suppl;abstr 4001).
16. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23:609-618
17. Bignami M, Casorelli I, Karran P. Mismatch repair and response to DNA-damaging antitumour therapies. Eur J Cancer 2003;39:2142-2149 (Review).
18. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefi t from fl uorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349: 247-257
19. Carethers JM, Smith EJ, Behling CA, Nguyen L, Tajima A, Doctolero RT, et al. Use of 5-fl uorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 2004;126:394-401.
20. Benatti P, Gafà R, Barana D, Marino M, Scarselli MP, Maestri I, et al. Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res 2005;11:8332-8340
21. Sargent DJ, Marsoni S, Thibodeau SN, Labianca R, Hamilton SR, Torri V, et al. Confi rmation of defi cient mismatch repair (dMMR) as a predictive marker for lack of benefi t from 5-FU based chemotherapy in stage II and III colon cancer: A pooled molecular reanalysis of randomized chemotherapy trials. J Clin Oncol 2008;26:15S (suppl; abstr 4008).
22. Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J, et al. Mismatch repair status in the prediction of benefi t from adjuvant fl uorouracil chemotherapy in colorectal cancer. Gut 2006;55:848-855
23. Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J, et al. The effi cacy of adjuvant chemotherapy with 5-fl uorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer 2009;45:365-373
24. Glimelius B, Dahl O, Cedermark B, Jakobsen A, Bentzen SM, Starkhammar H, et al. Adjuvant chemotherapy in colorectal cancer: A joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncol 2005;44:904-912
25. Chang GJ, Rodiguez-Bigas MA, Skibber JM, Moyer VA. Lymph node evaluation and survival after curative resection of colon cancer: Systematic review. J Natl Cancer Inst 2007;99:433-441
26. Wright FC, Law CH, Berry S, Smith AJ. Clinically important aspects of lymph node assessment in colon cancer. J Surg Oncol 2009;99:248-255
27. Azzoni C, Bottarelli L, Campanini N, Di Cola G, Bader G, Mazzeo A, et al. Distinct molecular patterns based on proximal and distal sporadic colorectal cancer: Arguments for different mechanisms in the tumorigenesis. Int J Colorectal Dis 2007;22:115-126
28. H emminki A, Mecklin JP, Jä r vinen H, Aaltonen LA, Joensuu H. Microsatellite instability is a favourable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 2000;119:921-928
29. Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B. Association of tumour site and sex with survival benefi t from adjuvant chemotherapy in colorectal cancer. Lancet 2000;355(9217):1745-1750
30. Dahl O, Fluge Ø , Carlsen E, Wiig JN, Myrvold HE, Vonen B, et al. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. Acta Oncol 2009;48:368-376
31. Wils J. Adjuvant treatment of colon cancer: Past present and future. J Chemother 2007;19:115-122
32. Beglund Å , Cedermark B, Glimelius B. Is it deleterious to delay the start of adjuvant chemotherapy in colon cancer stage III? Ann Oncol 2008;19:400-402
33. Kim GP, Colangelo LH, Wieand S, Paik S, Kirsch IR, Wolmark N, et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 2007;25:767-772
34. Bertagnolli MM, Niedzwiecki D, Compton CC, Hahn HP, Hall M, Damas B, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fl uorouracil, and leucovorin in stage III colon cancer: Cancer and leukemia group B protocol 89803. J Clin Oncol 2009;27:1814-1821
35. Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG, et al. Molecular predictors of survival of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001;344:1196-1206
36. Aranha O, Benson AB, 3rd. Adjuvant therapy for colon cancer. Curr Gastroenterol Rep 2007;9:415-421